Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable.
In type 2 diabetes, sitagliptin, in combination with a sulphonylurea, only provides modest efficacy in terms of HbA1c levels and increases the risk of hypoglycaemia.
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017277:Drug Approval; D004359:Drug Therapy, Combination; D005060:Europe; D006801:Humans; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D054873:Dipeptidyl-Peptidase IV Inhibitors; D011719:Pyrazines; D013453:Sulfonylurea Compounds; D014230:Triazoles